Circassia Pharmaceuticals plc Company Review & Valuation
About Circassia Pharmaceuticals plc
Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.
The company's asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.
It is also developing various novel specialty treatments for COPD, including Spiriva substitute, Novel LABA/LAMA formulation, and novel COPD therapy formulation.
In addition, the company' development pipeline includes a range of treatments for allergies, such as cat allergy, grass allergy, house dust mite allergy, and ragweed allergy.
It has a collaboration agreement with AstraZeneca to promote Tudorza for COPD treatment, and has the US commercial rights to late-stage COPD product Duaklir.
Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.